| 1 | The new X-ray imaging and biomedical application beamline BL13HB at SSRF显示文摘A new X-ray imaging and biomedical application beamline(BL13HB)has been implemented at the Shanghai Radiation Synchrotron Facility(SSRF)as an upgrade to the old X-ray imaging and biomedical application beamline(BL13W1).This is part of the Phase II construction project of the SSRF.The BL13HB is dedicated to 2D and 3D static and dynamic X-ray imaging,with a field of view of up to 48.5 mm×5.2 mm and spatial resolution as high as 0.8μm.A super-bending magnet is used as the X-ray source in BL13HB,which has a maximum magnetic field of 2.293 T.The energy range of monochromatic X-ray photons from a double-multiplayer monochromator was 8–40 keV,and the white beam mode was provided on the beamline for dynamic X-ray imaging and dynamic X-ray micro-CT.While maintaining the previous experimental setup of BL13W1,new equipment was added to the beamline experimental station.The beamline is equipped with different sets of X-ray imaging detectors for several experimental methods such as micro-CT,dynamic micro-CT,and pair distribution function.The experimental station of BL13HB is designed specifically for various in situ dynamic experiments,and BL13HB has been open to users since June 2021. | Jian‑Feng Ji Han Guo Yan‑Ling Xue Rong‑Chang Chen Ya‑Nan Fu Guo‑Hao Du Biao Deng Hong‑Lan Xie Ti‑Qiao Xiao | 2023 | Nuclear Science and Techniques2023，34，12： | 0 |
| 2 | 血浆Epstein-Barr病毒DNA对鼻咽癌患者颈部淋巴结残留的诊断和预后价值:一项回顾性研究显示文摘背景与目的目前,诊断鼻咽癌(nasopharyngeal carcinoma,NPC)患者进行联合化疗的根治性放疗后是否出现颈部淋巴结残留及治疗是具有挑战性的。我们分析了颈部淋巴结残留NPC患者的预后,并评估了Epstein-Barr病毒(Epstein-Barr virus,EBV)DNA对这些患者的诊断和预后的价值。方法本研究纳入了82例NPC患者,他们在完成抗肿瘤治疗后被诊断出疑似发生颈部淋巴结残留。在开始进行治疗和颈部清扫之前,使用定量聚合酶链反应(quantitative polymerase chain reaction,qPCR)检测患者血浆EBV DNA水平。21例患者接受了细针抽吸细胞学检查(fine needle aspiration cytology,FNAC)。所有患者均接受了颈部清扫术和术后病理检查,以明确颈淋巴结的性质。采用Kaplan-Meier法计算总生存期(overall survival,OS)、无进展生存期(progression-free survival,PFS)、无远处转移生存期(distant metastasis-free survival,DMFS)和局部区域无复发生存期(locoregional relapse-free survival,LRRFS),并使用log-rank检验进行比较。采用Cox比例风险模型计算置信区间(confidenceinterval,CI)为95%时的风险比(hazardratio,HR)。采用多变量分析估计潜在预后因素对生存的影响。结果中位随访52.6个月后,与术后病理结果阴性的患者相比,结果阳性的颈淋巴结残留患者的3年PFS率显著降低(49.9%vs.83.3%,P=0.008)。在颈淋巴结残留的鼻咽癌患者中,术前血浆EBV DNA>0拷贝/mL的患者的3年PFS率低于未检测到EBV DNA的患者(43.7%vs.61.1%,P=0.031)。此外,将FNAC与术前EBVDNA检测相结合可提高诊断灵敏度。多变量分析显示,术后颈部淋巴结残留病理结果阳性是PFS的独立预后因素,术前可检测到血浆EBV DNA是OS的独立预后因素。结论采用FNAC联合术前EBV DNA检测可提高对颈部淋巴结残留的NPC的诊断敏感性。与未检出EBV DNA的患者相比,术前检出血浆EBV DNA的患者预后较差,并且可能需要更积极的治疗方案。 | Sai‑Lan Liu Xue‑Song Sun Xiao‑Yun Li Lin‑Quan Tang Qiu‑Yan Chen Huan‑Xin Lin Yu‑Jing Liang Jin‑Jie Yan Chao Lin Shan‑Shan Guo Li‑Ting Liu Yang Li Hao‑Jun Xie Qing‑Nan Tang Hu Liang Ling Guo Hai‑Qiang Mai | 2019 | 癌症2019，38，9： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员